Key Highlights

  • Phillips 66 (NYSE:PSX) reports before the open on October 28, 2026, with EPS seen at USD 11.84, a figure that looks high and needs checking, after refiners fell 8% to 10% on Tuesday.
  • Exxon Mobil (NYSE:XOM) reports before the open on October 30, 2026, with EPS seen at USD 4.10 on about USD 105.4 billion of revenue, while Brent trades above USD 109 and Middle East supply risk remains in the headlines.
  • AbbVie (NYSE:ABBV) reports on October 30 with consensus EPS near USD 3.73 on about USD 17.3 billion of revenue, after a biotech rally and a valuation downgrade for Moderna that left sector sentiment divided.
  • Chevron is seen at USD 4.86 and HF Sinclair at USD 7.67, so the energy group reports into a volatile oil market while pharma reports into split sentiment about biotech.

Exxon Mobil (NYSE:XOM): Refining margin test

Exxon Mobil (NYSE:XOM) is forecast at EPS of USD 4.10 on revenue near USD 105.4 billion. The company combines production, refining and chemicals, so a high crude price helps its upstream earnings while a refiner selloff signals pressure on margins downstream. Investors will look at production volumes, refining margins and cash returns through dividends and buybacks. The date comes from a single earnings calendar, so it should be confirmed against the company's own notice. Analysts will also ask whether the disruption in the Strait of Hormuz has changed shipping costs, insurance and the timing of cargoes, because those items can shift reported margins. Capital spending plans, including new projects and the pace of share repurchases, are other areas where management commentary tends to move the stock. The figures above for Exxon Mobil (NYSE:XOM) come from published market data and company statements and may be revised. Chevron (NYSE:CVX) is forecast at EPS of USD 4.86 on revenue near USD 61.3 billion. The estimate is higher per share than Exxon Mobil's because of differences in share count and earnings mix, not necessarily stronger operations. The company will also be asked about capital spending, buyback pace and any change to its production outlook, which often drive the share price more than the quarter itself. Dividend growth is another watched item, because oil majors are held by many income-focused investors and any change is closely read. Crude quotes differ across published sources by up to about USD 6, so any price level in an analyst model deserves a check. The Federal Reserve decision on October 28, 2026 and a 10-year yield near 4.995% affect energy valuations, and a ceasefire or escalation in the Middle East could move crude sharply.

Phillips 66 (NYSE:PSX): Oil major scale test

Phillips 66 (NYSE:PSX) is forecast at EPS of USD 11.84. That figure looks high, and an estimate this large may reflect a data error or a one-off item, so it should be verified against other providers and the company's own release. Phillips 66 combines refining with midstream, chemicals and marketing, so its results depend on several lines at once. The refining line moves with the crack spread, which is the difference between the price of refined products and the price of crude. A wide spread lifts profit, while a narrow spread squeezes it, even when headline crude prices are high. Chemicals and midstream earnings add stability, but refining remains the swing factor. The figures above for Phillips 66 (NYSE:PSX) come from published market data and company statements and may be revised. HF Sinclair (NYSE:DINO) is forecast at EPS of USD 7.67, a figure that also looks high and may be affected by data errors, since one calendar lists the company under its former name, HollyFrontier. The company is a pure-play refiner, so its earnings swing more with margins than a diversified peer's. Refiners fell 8% to 10% on October 27, 2026, a drop whose cause was not established, so the reports are the first chance to hear from managers. Investors will ask about throughput, product inventories, crude costs and shareholder returns. Management comments on turnarounds, planned maintenance and export demand for diesel and jet fuel may also shape expectations for the rest of the year. Brent above USD 109, with published quotes differing by several dollars, and Middle East disruption can push crude costs up faster than product prices. A Houthi claim of an attack on Ras Tanura, as reported and not confirmed, adds to supply risk.

AbbVie (NYSE:ABBV): Pharma growth test

AbbVie (NYSE:ABBV) is forecast to earn USD 3.73 a share on USD 17.3 billion of revenue. For a large pharmaceutical group the revenue line is dominated by a few products, so investors look at growth in each one and at what management says about pricing, rebates and competition. The date of October 30, 2026 comes from the same calendar as the estimates, so both should be confirmed against the company's own announcement. Because the consensus is an average, a small beat is common and the reaction usually depends on guidance more than on the quarter. Drug-pricing policy and the pace of new launches are also in focus, since both shape how much of the revenue can be sustained over the next several years. The figures above for AbbVie (NYSE:ABBV) come from published market data and company statements and may be revised. Pharma stocks trade partly on sentiment toward biotech, and that sentiment has been mixed. A rally in biotech shares has lifted valuations, while the downgrade of Moderna's valuation shows investors still discriminate between pipelines. For AbbVie (NYSE:ABBV), the company has relied on immunology drugs such as Skyrizi and Rinvoq to offset the loss of exclusivity on Humira, so the pace of that handover is a recurring theme. Management commentary on pipeline milestones, patent timelines and pricing policy can shift expectations for several quarters, which is why the call often matters more than the headline figures. Currency effects can also change reported revenue, because a large share of sales comes from outside the United States and a stronger dollar reduces translated results. Risks include drug-pricing pressure, patent expirations, trial setbacks and a rise in yields that makes defensive stocks less attractive.

Where Things Stand

The answer is that energy and pharma give opposite reads this week: refiners and oil majors are driven by crude and margins, while AbbVie is driven by drug growth and guidance. Phillips 66 reports first, on October 28, followed by Exxon Mobil (NYSE:XOM) and AbbVie on October 30. All figures are approximate consensus numbers, and the Federal Reserve decision on October 28 is the next macro catalyst. This is not investment advice.